Lymphoma, rheumatoid arthritis, and TNFα antagonists

Joint Bone Spine

Volumn 77, Issue 3, 2010, Pages 195-197

  Mariette, Xavier ^a  

^a BICÊTRE HOSPITAL   (France)

Author keywords

Lymphoma; Rheumatoid arthritis; TNF antagonists

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; ETANERCEPT; INFLIXIMAB; METHOTREXATE; MONOCLONAL ANTIBODY; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ALLOTRANSPLANTATION; ANKYLOSING SPONDYLITIS; BINDING AFFINITY; CANCER RISK; CLINICAL TRIAL; CROHN DISEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; EDITORIAL; EPSTEIN BARR VIRUS; GRANULOMA; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOMA; MEMBRANE BINDING; NONHODGKIN LYMPHOMA; PATHOGENESIS; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; SJOEGREN SYNDROME; T LYMPHOCYTE; TUBERCULOSIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOMA; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77952675245     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2010.02.002     Document Type: Editorial

References (16)

1. Zintzaras E., Voulgarelis M., and Moutsopoulos H.M. The risk of lymphoma development in auto-immune diseases: a meta-analysis. Arch Intern Med 165 20 (2005) 2337-2344
2. Baecklund E., Iliadou A., Askling J., et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 54 (2006) 692-701
3. Mariette X. Lymphomas complicating Sjögren's syndrome and hepatitis C virus infection may share a common pathogenesis: chronic stimulation of rheumatoid factor B cells. Ann Rheum Dis 60 (2001) 1007-1010
4. Beaugerie L., Brousse N., Bouvier A.M., et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 374 (2009) 1617-1625
5. Kamel O.W., van de Rijn M., Weiss L.M., et al. Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med 328 (1993) 1317-1321
6. Wolfe F., and Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 56 (2007) 1433-1439
7. Mariette X., Cazals-Hatem D., Warszawki J., et al. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 99 (2002) 3909-3915
8. Askling J., Baecklund E., Granath F., et al. Anti-TNF therapy in RA and risk of malignant lymphomas Relative risks and time-trends in the Swedish Biologics Register. Ann Rheum Dis 68 (2009) 648-653
9. Setoguchi S., Solomon D.H., Weinblatt M.E., et al. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum 54 (2006) 2757-2764
10. Bongartz T., Sutton A.J., Sweeting M.J., et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295 (2006) 2275-2285
11. Bongartz T., Warren F., Mines D., et al. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Ann Rheum Dis 68 (2009) 1177-1183
12. Mariette X, Tubach F, Bagheri H, et al. Lymphoma in patients treated with anti-TNF. Results of the 3-year prospective French RATIO registry. Ann Rheum Dis 2009 10;69:400-8.
13. Baran-Marszak F., Laguillier C., Youlyouz I., et al. Effect of tumor necrosis factor alpha and infliximab on apoptosis of B lymphocytes infected or not with Epstein-Barr virus. Cytokine 33 (2006) 337-345
14. Miceli-Richard C., Gestermann N., Amiel C., et al. Effect of methotrexate and anti-TNF on Epstein-Barr virus T-cell response and viral load in patients with rheumatoid arthritis or spondylarthropathies. Arthritis Res Ther 11 (2009) R77
15. Scallon B., Cai A., Solowski N., et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 301 (2002) 418-426
16. Tubach F., Salmon D., Ravaud P., et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 60 (2009) 1884-1894